DNA methylation analysis of SOX17, MGMT and MLL3 genes in CTCs in early prostate cancer patients

Postgraduate Thesis uoadl:2879742 325 Read counter

Unit:
Κατεύθυνση Κλινική Χημεία
Library of the School of Science
Deposit date:
2019-07-25
Year:
2019
Author:
Tserpeli Victoria
Supervisors info:
Λιανίδου Ευρύκλεια, Καθηγήτρια Αναλυτικής Χημείας-Κλινικής Χημείας, Τμήμα Χημείας, Σχολή Θετικών Επιστημών, Εθνικό και Καποδιστριακό Πανεπιστημίου Αθηνών
Original Title:
Μελέτη μεθυλίωσης των γονιδίων SOX17, MGMT και MLL3 σε Κυκλοφορούντα Καρκινικά Κύτταρα ασθενών με πρώιμο καρκίνο του προστάτη
Languages:
Greek
Translated title:
DNA methylation analysis of SOX17, MGMT and MLL3 genes in CTCs in early prostate cancer patients
Summary:
Prostate cancer is considered to be the second lethal cancer among men while it is estimated that one out of six men will be newly diagnosed with the disease. It is widely accepted that the main cause of death among cancer patients is the metastatic disease. Liquid biopsy, based on the analysis of circulating tumor cells (CTCs), provides the opportunity to noninvasively and repeatedly sample representative tumor cells, providing information concerning not only tumor burden but also the heterogeneity and the progression of the tumor.
The combination of both genetic and epigenetic alternations, and especially DNA methylation, has been correlated with the initiation and the progression of carcinogenesis. The aim of this diploma thesis was the methylation status of tumor suppressor genes in CTCs in early prostate cancer patients.
The methylation status of the SOX17, MGMT and MLL3 genes was evaluated by a real-time methylation specific PCR (qMSP) method. These genes were specifically selected because of their role as tumor suppressor genes. The main principle of the qMSP method consists in the selective amplification of the methylated sequence, which is achieved by using the appropriate pairs of primers.
This method was applied in a total number of 79 CTC-samples. CTCs were isolated with a novel in vivo device CellCollector TM (Gilupi) from patients with early prostate cancer. All 79 samples were analyzed in parallel with three other techniques: a) the FDA approved CellSearch®, b) the Epispot, and c) Imuunofluorescence (IF). 20 samples out of the 79 were negative in all 3 CTC-detection techniques and that’s why these 20 samples were used a control group. All 79 samples were analyzed and as expected no methylation, for any of the three genes, was detected in the control group. However, in the remaining 59 samples methylation was detected only for the SOX17 gene (8/59, 13,6%).
Main subject category:
Science
Keywords:
CTCs, SOX17, MGMT, MLL3, Real-time MSP
Index:
Yes
Number of index pages:
8
Contains images:
Yes
Number of references:
157
Number of pages:
133
Διπλωματική Εργασία Βικτωρίας Τσερπέλη 23-7-2019.pdf (4 MB) Open in new window